Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Curcumin Formulation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female age ≥ 50.~* Diagnosed with probable AD using NINDS-ADRDA research criteria. MMSE score ≥5 and ≤20.~* No history of significant psychiatric or non-AD neurological disease.~* An available caregiver to monitor and administer medication and to accompany the subject to every clinical visit.~* On stable doses of concomitant medications for at least one month prior to starting study medication.~Exclusion Criteria:~* Current or recent major psychiatric illness that meets DSM-IV criteria (i.e. bipolar disorder, schizophrenia).~* Significant uncontrolled systemic illness (i.e. chronic renal failure, chronic liver disease, poorly controlled diabetes, or poorly controlled congestive heart failure).~* Recent history of gastrointestinal bleeding or ulceration.~* Alcoholism or substance abuse within the past year per DSM-IV criteria.~* Familial, autosomal dominant Alzheimer's disease due to a mutation in a known gene (Presenilin-1, Presenilin-2, or Amyloid Precursor Protein).

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- curcumin (Type: ACTIVE_COMPARATOR): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).